PMID- 12112525
OWN - NLM
STAT- MEDLINE
DCOM- 20020813
LR  - 20220311
IS  - 1045-2257 (Print)
IS  - 1045-2257 (Linking)
VI  - 34
IP  - 4
DP  - 2002 Aug
TI  - Clinical significance of alterations of chromosome 8 detected by fluorescence in 
      situ hybridization analysis in pathologic organ-confined prostate cancer.
PG  - 363-71
AB  - Loss of 8p22 and gain of 8q24 are known to be common chromosomal alterations in 
      prostate cancer. We have previously demonstrated that concurrent 8q24 
      overrepresentation and 8p22 loss were associated with a poor prognosis in 
      patients with high-grade, locally advanced prostate cancer. We evaluated the 
      alteration of 8p22 and 8q24 in a large cohort of pathologic organ-confined 
      prostate cancer using fluorescence in situ hybridization (FISH) analysis. All 195 
      patients with Gleason scores > 5, pathologic stage T(2)N(0)M(0) (pT(2)N(0)M(0)) 
      prostate cancer, who underwent a radical prostatectomy at the Mayo Clinic between 
      1987 and 1991, and for whom blocks were available, were selected for this study. 
      The median follow-up period was 9.5 years, and endpoints of this study were 
      biochemical and clinical disease progression. The latter includes local as well 
      as systemic disease progression. FISH analysis using paraffin-embedded tissues 
      was performed for 8p22 (LPL), centromere 8 (8cen), and 8q24 (MYC) and was 
      successful for 156 tumors (80.0%). Of these tumors, 104 (66.6%) had one or more 
      numeric alterations of the 3 loci evaluated. An increased copy number of 8q24 was 
      observed in 66 (42.3%) tumors, of which 20 (12.8%) had an additional increase 
      (AI) of 8q24, and 46 (29.5%) had a gain of 8q24 with an equivalent gain of 8cen. 
      Losses and gains of 8p22 were detected in 81 (51.9%) and 20 (12.8%) tumors, 
      respectively. An AI of 8q24 was significantly associated with the tumor Gleason 
      score (P = 0.042). Univariate analysis indicated that loss of 8p22 was a 
      significant predictor of biochemical and clinical disease progression (P = 0.025 
      and P = 0.011, respectively). Furthermore, the group with loss of 8p22 concurrent 
      with an AI of 8q24 (Loss 8p22-any 8cen-AI 8q24) had an increased rate of 
      biochemical disease progression (P = 0.052). Multivariate analysis demonstrated 
      that neither individual nor the Loss-any-AI combination of alterations was a 
      significant independent predictor of disease progression when adjusting for 
      Gleason score, preoperative PSA levels, and DNA ploidy. These data suggest that 
      loss of 8p22 is associated with a poor prognosis, specifically when it is 
      accompanied by AI of 8q24 in pT(2)N(0)M(0) prostate cancer.
CI  - Copyright 2002 Wiley-Liss, Inc.
FAU - Tsuchiya, Norihiko
AU  - Tsuchiya N
AD  - Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, 
      USA.
FAU - Slezak, Jeffrey M
AU  - Slezak JM
FAU - Lieber, Michael M
AU  - Lieber MM
FAU - Bergstralh, Erik J
AU  - Bergstralh EJ
FAU - Jenkins, Robert B
AU  - Jenkins RB
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Genes Chromosomes Cancer
JT  - Genes, chromosomes & cancer
JID - 9007329
RN  - 0 (Genetic Markers)
SB  - IM
MH  - Allelic Imbalance/genetics
MH  - *Chromosome Aberrations
MH  - Chromosomes, Human, Pair 8/*genetics
MH  - Cohort Studies
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Genetic Markers/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Neoplasm Staging/methods
MH  - Prostatectomy
MH  - Prostatic Neoplasms/chemistry/*genetics/*pathology/surgery
MH  - Survival Rate
EDAT- 2002/07/12 10:00
MHDA- 2002/08/14 10:01
CRDT- 2002/07/12 10:00
PHST- 2002/07/12 10:00 [pubmed]
PHST- 2002/08/14 10:01 [medline]
PHST- 2002/07/12 10:00 [entrez]
AID - 10.1002/gcc.10064 [doi]
PST - ppublish
SO  - Genes Chromosomes Cancer. 2002 Aug;34(4):363-71. doi: 10.1002/gcc.10064.